Monthly Archives: March 2017

Xenon Pharmaceuticals Falls as Acne Drug Fails Study, Pulse Biosciences Submits 510(k) to FDA

NEW YORK, NY / ACCESSWIRE / March 27, 2017 / Investors are working through a mixed bag of stock price news as both companies are seeking to build on earlier momentum. Xenon reported troubling news earlier in the week, while Pulse continued to work on the second part of their therapeutic solution.

RDI Initiates
Coverage:

Xenon Pharmaceuticals
Inc. https://ub.rdinvesting.com/news/?ticker=XENE

Pulse Biosciences
Inc. https://ub.rdinvesting.com/news/?ticker=PLSE

Xenon Pharmaceuticals fell off the cliff before the opening bell, dropping 52.79% to close at $4.65 on Friday. The stock traded between $4.30 and $5.00 on volume of 3,269,690 shares traded. Investor rumors of a looming bankruptcy filing to be done over the weekend prompted the selloff. On March 24th, the company announced its XEN801, the sole candidate in the FDA pipeline, did not meet efficacy endpoints in its most recent Phase 2 clinical trial. The drug is intended as a treatment for patients with moderate to severe acne.

Xenon’s President and Chief Executive Officer, Dr. Simon Pimstone said, “the topline clinical results do not support this hypothesis or the continued development of XEN801.” Investor sentiment over the future of the stock is mixed. Some investors maintain the reason for the fall in stock price was that stock was oversold, while other predict an even greater drop to below $2 a share. Xenon has reported a loss of $23 million or $1.48 a share for the year 2016, and it has reported a significant decrease in collaboration revenue in the year 2016 from the same reported in the previous year. Cash, cash equivalent and marketable securities were $64.15 million of the total assets of $67.5 million as on December 31, 2016. While Xenon’s CEO remains optimistic amid the spate of bad news, investors await future positive news that will restore confidence in the company and its future.

Access RDI’s Xenon Pharmaceuticals Research Report at: https://ub.rdinvesting.com/news/?ticker=XENE

Pulse Biosciences advanced 17.19% to close at $30.34 on Friday. The stock traded between a high of $30.61 and low of $25.62 on volume of 760,447 shares traded. The advance was in part stimulated by news that there is a development of a drug that will be compatible with their recently submitted 510(k) device application to the FDA.

Pulse Biosciences submitted a 510(k) application to the FDA for its PulseTx(TM) System. Darrin Uecker, CEO and President of Pulse Biosciences said, “The submission is an important step to improve healthcare by delivering our unique technology to both physicians and their patients.” At the end of the reporting period of December 31, 2016, the company had cash, cash equivalents and investments totaling $16.4 million and the company has reported a loss of $0.21 a share and $0.86 a share for the fourth quarter and full year of 2016 respectively.

Access RDI’s Pulse Biosciences Research Report at: https://ub.rdinvesting.com/news/?ticker=PLSE

Our Actionable Research on Xenon Pharmaceuticals Inc. (NASDAQ: XENE) and Pulse Biosciences Inc. (NASDAQ: PLSE) can be downloaded free of charge at Research Driven Investing.

Research Driven
Investing

We are committed to providing relevant and actionable information for the self-directed investor. Our research is reputed for being a leader in trusted, in-depth analysis vital for informed strategic trading decisions. The nimble investor can leverage our analysis and collective expertise to execute a disciplined approach to stock selection.

RDInvesting has not been compensated; directly or indirectly; for producing or publishing this document.

Disclaimer: This article is written by an independent contributor of RDInvesting.com and reviewed by Nadia Noorani, CFA® charter holder. RDInvesting.com is neither a registered broker dealer nor a registered investment advisor. For more information, please read our full disclaimer at www.rdinvesting.com/disclaimer.

CONTACT

For any questions, inquiries, or comments reach out to us directly at:

Address:

Research Driven Investing, Unit #901 511 Avenue of the Americas, New York, NY, 10011

Email:

contact@rdinvesting.com

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.

SOURCE: RDInvesting.com

ReleaseID: 458212

Nike and Under Armour Stepping Up Their Competitive Spirit

NEW YORK, NY / ACCESSWIRE / March 27, 2017 / Shoe retailers have experienced a number of challenges growing from consumer demand and retail locations. Both companies have been hit with troubling earnings numbers, and they plan to act to re-engage customers and re-establish investor confidence.

RDI Initiates
Coverage:

Under Armour Inc. https://ub.rdinvesting.com/news/?ticker=UA

Nike Inc. https://ub.rdinvesting.com/news/?ticker=NKE

Under Armour advanced 4.13% to close at $18.16 on Friday. The stock traded between $18.52 and $17.98 on volume of 6.70 million shares traded. The upward movement is a bit of a surprise given the recent bad news for investors. The head of finance, Chip Molloy, left after only a single year on the job, eroding investor confidence. Their corporate bonds were reduced to junk bond status by Standard and Poor’s, reducing it to BB-plus rating. The rating company also gave Under Armour a negative outlook status, so yet another drop in its rating is possible.

However, the other major ratings company, Moody’s bumped the company’s outlook down from “stable” to “negative” but did chose not to downgrade its corporate bond rating. One possible reason for Moody’s patience is Under Armour’s entry into the high fashion segment. Its new $300 ArchiTect Futurist shoe to be launched on March 30th, has a “next-gen design” that comes with a number of high-tech features such as its 3D-printed midsole, which promises its buyers “infinite cushioning and support” for their feet.

Access RDI’s Under Armour Research Report at:
https://ub.rdinvesting.com/news/?ticker=UA

Nike stock advanced $1.79 to close at $56.36 on Friday. The stock traded in a relatively narrow range between $56.64 and $55.12 on volume of 14.44 million shares traded. The company met their revenue expectations in their latest financial report, but there was a loss in sales that was offset by savings in administrative costs and lower taxes paid. While this caused the stock to take a dip earlier in the week, Friday’s close makes room for optimism. The company has labeled its most recent efforts to spur sales as a “triple double”: – targeting innovation, supply chain speed of delivery, and engaging consumers through the offering of digital memberships.

In corporate news, one-time member of Barron’s Top 30 of the Best CEOs, Nike’s Mark Parker, lost his place on the latest list. Parker remains one of the world’s top CEO’s, but the bankruptcy filing of retail outlet The Sports Authority were a drag on the company’s performance.

Access RDI’s Nike Research Report at: https://ub.rdinvesting.com/news/?ticker=NKE

Our Actionable Research on Under Armour Inc. (NYSE: UA) and Nike (NYSE: NKE) can be downloaded free of charge at Research Driven Investing.

Research Driven
Investing

RDInvesting has not been compensated; directly or indirectly; for producing or publishing this document.

CONTACT

For any questions, inquiries, or comments reach out to us directly at:

Address:

Research Driven Investing, Unit #901 511 Avenue of the Americas, New York, NY, 10011

Email:

contact@rdinvesting.com

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.

SOURCE: RDInvesting.com

ReleaseID: 458210

Shipping Industry Struggles Continue in 2017: Today’s Reports on DryShips and Top Ships

NEW YORK, NY / ACCESSWIRE / March 27, 2017 / Dryships is currently trading below book value, raising the question of the company being undervalued. The company, however, has just completed a $200 million dilutive capital raise. The company’s shares are currently valued at $1.35 per share with a total of 152 million shares outstanding. The company’s share value currently stands at $2.82 in book value, representing a 100% upside on the current market value of its shares.

Industry experts say the current dip in stock value does not necessarily translate to an undervalued share price, but the shares remain too risky to hold. The dip is owed to its increasing operating costs. Experts also point to diminishing asset value of Dryships, as the cash will probably be used to buy value-destructive assets. The fluctuations are affecting the company’s overall market value negatively, but a positive cash flow has been predicted in the coming days. Investors can expect continued dilution and impairment of charges in the foreseeable months.

Access RDI’s DryShips Research Report at: https://ub.rdinvesting.com/news/?ticker=DRYS

Top Ship’s shares closed the day on a high, trading at $1.16 per share, representing a 4.5% increase from the previous day’s $1.11 per share. The company recently announced that if the discounts persist, going private would be the next option on the horizon. Sabra Capital LLC is the opportunistic buyer of Top Ships shares, with its equity share currently standing at 4.5%.

The steep discount to Net Asset Value might be making the company illiquid, but Sabra Company LLC has continuously dismissed the negative trend, citing that the weakening stock does not reflect the fundamentals of the company. The Net Asset Value is currently delaying large free cash flow generation and capital market activity. The cash flow impediments are affecting the company’s commitments to add more vessels. It is also noteworthy that Top Ships started reconstituting its fleet on April 2014, igniting a $30 million secondary stock offer.

Access RDI’s Top Ships Research Report at: https://ub.rdinvesting.com/news/?ticker=TOPS

Our Actionable Research on DryShips Inc. (NASDAQ: DRYS) and Top Ships Inc. (NASDAQ: TOPS) can be downloaded free of charge at Research Driven Investing.

Research Driven
Investing

RDInvesting has not been compensated; directly or indirectly; for producing or publishing this document.

CONTACT

For any questions, inquiries, or comments reach out to us directly at:

Address:

Research Driven Investing, Unit #901 511 Avenue of the Americas, New York, NY, 10011

Email:

contact@rdinvesting.com

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.

SOURCE: RDInvesting.com

ReleaseID: 458204

Micron Technology and NVIDIA Show Further Growth is Ahead

NEW YORK, NY / ACCESSWIRE / March 27, 2017 / Good times are ahead for both Micron and NVIDIA as both companies are seeing higher demand for their products over the next two quarters. Micron is beating analyst’s estimates, while NVIDIA’s artificial intelligence technology continues to be adopted by enterprise companies. Also, one of NVIDIA’s CEO’s gets special recognition from a major financial publication.

RDI Initiates
Coverage:

Micron Technology,
Inc. https://ub.rdinvesting.com/news/?ticker=MU

NVIDIA Corporation https://ub.rdinvesting.com/news/?ticker=NVDA

Micron Technology advanced 7.40% to close at $28.43 on Friday. The stock traded between a daytime high of $29.87 and low of $28.16 on volume of 107.5 million shares traded. The company’s stock price has steadily increased over the last 12 months based on global demand for their microprocessor chips that can be used in a variety of computing devices. The demand, many analysts are predicting, will continue to remain high throughout the 3rd quarter of this year.

Micron’s fiscal 2nd quarter result and outlook for the 3rd quarter on March 24 has blown away analysts’ estimates. Driven by higher DRAM prices and revenue growth across all business segments, Micron has reported 58 percent year-on-year growth and 17 percent sequential growth in revenue totally $4.65 billion for the fiscal 2nd quarter. Net income of $894 million or $0.77 a share and Non-GAAP earnings of $0.90 a share, surpassed analysts’ estimated Non-GAAP earnings of $0.86 a share. Most importantly, quarterly gross margin of 36.7 percent has nearly doubled year-on-year and Micron is now expecting earnings in the range of $1.43 a share to $1.57 a share on revenue of $5.2 billion to $5.6 billion range with gross margin in 44 percent to 48 percent range for the fiscal 3rd quarter.

Access RDI’s Micron Technology Research Report at: https://ub.rdinvesting.com/news/?ticker=MU

NVIDIA Corporation moved higher by 0.35% to close at $107.47 on Friday. The stock traded between $109.29 and $106.42 on volume of 10.99 million shares traded. News on Friday has client Tencent Cloud planning to adopt NVIDIA Tesla GPU accelerators in order to help advance artificial intelligence capabilities for their enterprise customers. Ian Buck, head of Accelerated Computing at NVIDIA, said that, “Through Tencent Cloud, more companies will have access to NVIDIA’s deep learning platform, the world’s most broadly adopted AI platform.”

In other corporate news, Jen-Hsun “Jensen” Huang was a new name that appeared on Barron’s Top 30 list of CEOs. The list was made from CEOs who “demonstrated an ability to outperform during a slow patch for commerce.” With the combination of advancing technologies and a quality leadership, NVIDIA’s stock has gained more than 200 percent in last 1 year and has “overweight” ratings from the consensus of analysts.

Access RDI’s NVIDIA Research Report at: https://ub.rdinvesting.com/news/?ticker=NVDA

Our Actionable Research on Micron Technology, Inc. (NASDAQ: MU) and NVIDIA Corporation (NASDAQ: NVDA) can be downloaded free of charge at Research Driven Investing.

Research Driven
Investing

RDInvesting has not been compensated; directly or indirectly; for producing or publishing this document.

CONTACT

For any questions, inquiries, or comments reach out to us directly at:

Address:

Research Driven Investing, Unit #901 511 Avenue of the Americas, New York, NY, 10011

Email:

contact@rdinvesting.com

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.

SOURCE: RDInvesting.com

ReleaseID: 458208

Drug Manufacturers Continue to be Plagued by Pricing Concerns: Today’s Research Reports on Valeant Pharmaceuticals and Mylan

NEW YORK, NY / ACCESSWIRE / March 27, 2017 / Valeant’s share price took a 1.01% dip today, to close at $10.75 compared to the previous day’s market value of $10.86. Valeant CEO Joseph Papa was paid an impressive $62.7 million as compensation last year, amid a high debt ratio, an accounting crisis and a fading company image. The company has increased focus in franchising skincare and stomach treatment drugs, in a bid to offset a $30 billion debt.

Valeant’s 2016 tenure was however counter-productive, with the new CEO recording a 7.4% decline in revenues amounting to $2.41 billion in losses. The low performance was fueled by the exit of hedge fund manager William Ackman, the company’s most prominent supporter. The future however looks optimistic, with Valeant having the board’s full support.

Access RDI’s Valeant Pharmaceuticals Research Report at: https://ub.rdinvesting.com/news/?ticker=VRX

Mylan’s share price closed the day on a low, dipping 1.55% by the close of business today. The company started the day on a high at the ring of the bell, but things took a turn for the worst by midday but rumors of a pending takeover saw a sharp spike in the share’s market value. The trend however was disrupted by the close of business, with the company closing the day at $39.23 per share, representing the 1.55% dip discussed earlier. A change in management would mean an automatic change in the share price with an upward trend even the more likely.

It is rumored that Pfizer will be taking over Mylan Br, and it will be interesting to see how things turn out tomorrow. The news of the takeover has not yet been confirmed. However, with the fluctuating share price, there seems to be enough metal and fire in the kiln to safely speculate a takeover. If it so happens, the share price is expected to rise with shareholders remaining optimistic. With the President’s proposed tax reform agenda, specifically centered on the pharmaceuticals company, regulatory effects border on the positive.

Access RDI’s Mylan Research Report at: https://ub.rdinvesting.com/news/?ticker=MYL

Our Actionable Research on Valeant Pharmaceuticals Intl Inc. (NYSE: VRX) and Mylan N.V. (NASDAQ: MYL) can be downloaded free of charge at Research Driven Investing.

RDI Initiates
Coverage on:

Valeant
Pharmaceuticals Intl Inc. https://ub.rdinvesting.com/news/?ticker=VRX

Mylan N.V. https://ub.rdinvesting.com/news/?ticker=MYL

Research Driven
Investing

RDInvesting has not been compensated; directly or indirectly; for producing or publishing this document.

CONTACT

For any questions, inquiries, or comments reach out to us directly at:

Address:

Research Driven Investing, Unit #901 511 Avenue of the Americas, New York, NY, 10011

Email:

contact@rdinvesting.com

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.

SOURCE: RDInvesting.com

ReleaseID: 458203

Today’s Research Reports on Stocks to Watch: Ford Motor and Tesla

NEW YORK, NY / ACCESSWIRE / March 27, 2017 / Ford’s share value took a 0.43% plunge by the end of business today, to trade at $11.62 per share compared to the previous $11.67 per share. The company has already announced they expect losses by the end of 2017, with the performance attributed to the company’s expansion ambitions. The company is yet to launch its “fully driverless” vehicles. The profits will take a $1.4 billion plunge, with estimated pointing to a $9 billion adjusted pretax profit, down from last year’s $10.4 billion.

RDI Initiates
Coverage:

Ford Motor Company https://ub.rdinvesting.com/news/?ticker=F

Tesla Inc. https://ub.rdinvesting.com/news/?ticker=TSLA

The company, however, owes the decrease to their planned investment and investment in emerging opportunities, with a recovery expected to be realized by the end of 2018. Bob Shanks, Ford’s Chief Financial Officer on Thursday 23rd announced these projected results. The company’s core automaking business is expected to in 2017, with the company announcing its intentions to dive into new technology and infrastructure. This will, in turn, make the company explore more transportation-related products and services.

Access RDI’s Ford Motor Research Report at: https://ub.rdinvesting.com/news/?ticker=F

Tesla has been enjoying an upward trend in its share price, with the company experiencing a 3.29% increase to close the day at $263.16 per share. Industry experts owe the progressive trend to Tesla’s ability to turn a weakness into strength. The company is experiencing a “do-away” strategy as it announced earlier its intentions to get rid of its cheapest models.

The company yesterday on Frida, March 24th, 2017 announced its intentions to do away with the Model S sedan, its cheapest model to date. The auto company has finished raising $250 million in common shares last week, and an $850 million in convertible notes, to cater for the launch of the new Model 3. Wall Street, however, deemed this collection bordering on the low but had expected the company to raise more capital to facilitate the Model 3 launch. The automotive industry is adjusting to meet the new technological and regulatory demands, with Tesla showing no intentions of slowing down regarding market dominance.

Access RDI’s Tesla Research Report at: https://ub.rdinvesting.com/news/?ticker=TSLA

Our Actionable Research on Ford Motor Company (NYSE: F) and Tesla Inc. (NASDAQ: TSLA) can be downloaded free of charge at Research Driven Investing.

Research Driven
Investing

RDInvesting has not been compensated; directly or indirectly; for producing or publishing this document.

CONTACT

For any questions, inquiries, or comments reach out to us directly at:

Address:

Research Driven Investing, Unit #901 511 Avenue of the Americas, New York, NY, 10011

Email:

contact@rdinvesting.com

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.

SOURCE: RDInvesting.com

ReleaseID: 458200

Biotech Industry Continues to Provide Investors with Gains in 2017: Today’s Reports on Peregrine Pharmaceuticals and Novavax

NEW YORK, NY / ACCESSWIRE / March 27, 2017 / Peregrine Pharmaceuticals’ shares might be trading below the dollar mark, but the upward trend has been promising. The company’s shares rose today, to trade at $0.71 representing an impressive 4.33% rise. The industry overall has been performing well since Trump’s election, but alternating sentiments with regard to regulations act to increase volatility in performance on the stock market.

In a recent dramatic turn of events regarding the GOP Healthcare bill, there are still plenty of legislative battles the Department of Health and Human Services has to overcome. During the anticipation of the results of the vote on the bill from the House of Representatives, the biotech industry’s markets performance has been shaky, to say the least. The industry’s volatility has been attributed to the Trump’s administration ability to alter sentiments in an instant. Boitech’s ETFs came crumbling down recently after the President deemed drug prices as “astronomical”. Industry experts predict that a continued criticism of the industry’s pricing mechanisms would contribute to the sector’s diminishing profitability.

Access RDI’s Peregrine Pharmaceuticals Research Report
at: https://ub.rdinvesting.com/news/?ticker=PPHM

Novavax Inc. closed the day on a low. With the company’s share price taking a 0.79% dip by the end of business today. In a recent meeting between the industry’s stakeholders and the president resulted in Trump citing reduced regulations, with regard to pricing. Novavax’s share price is not as volatile as other companies’, with their share price fluctuating positively.

The President also promised to reduce drug regulations, and push for easier drug approvals. This move could act to positively impact the industry’s profitability with the SPDR S&P Biotech ETF XBI trading up by 0.82%, recovering from a 0.38% dip during the previous session. Industry players are still waiting for the industry to stabilize amid President Trump’s new regulations that are working to increase the industry’s volatility. New regulations associated with a corporate tax reduction form the current 35% to 15% are set to affect companies who export jobs abroad.

Access RDI’s Novavax Research Report at: https://ub.rdinvesting.com/news/?ticker=NVAX

Our Actionable Research on Peregrine Pharmaceuticals (NASDAQ: PPHM) and Novavax, Inc. (NASDAQ: NVAX) can be downloaded free of charge at Research Driven Investing.

RDI Initiates
Coverage on:

Peregrine
Pharmaceuticals https://ub.rdinvesting.com/news/?ticker=PPHM

Novavax Inc. https://ub.rdinvesting.com/news/?ticker=NVAX

Research Driven
Investing

RDInvesting has not been compensated; directly or indirectly; for producing or publishing this document.

CONTACT

For any questions, inquiries, or comments reach out to us directly at:

Address:

Research Driven Investing, Unit #901 511 Avenue of the Americas, New York, NY, 10011

Email:

contact@rdinvesting.com

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.

SOURCE: RDInvesting.com

ReleaseID: 458202

Increased Volume Spurs Stock Prices of Benitec Biopharma, Regulus Therapeutics

NEW YORK, NY / ACCESSWIRE / March 27, 2017 / Higher volumes were the order of the day for these two biotech stocks, as each stock saw a double digit percent increase in the price of their stocks. Regulus received an “outperform” endorsement from one investment firm, expressing confidence in the company in the midst of some uncertainty.

RDI Initiates
Coverage:

Benitec Biopharma
Ltd. https://ub.rdinvesting.com/news/?ticker=BNTC

Regulus Therapeutics
Inc. https://ub.rdinvesting.com/news/?ticker=RGLS

Benitec Biopharma advanced 18.50% to close at $2.69 on Friday. The stock traded between a high of $2.90 and an opening low of $2.37 on volume of 312,833 shares traded. The stock recovered from Thursday’s finish which was lower, down to $2.27 with a volume of 27,331 shares traded. Benitec Biopharma is an Australian company that develops treatments using its gene silencing therapy, DNA-directed RNA interference (ddRNAi) for chronic and life-threatening human diseases.

On March 13th of this year, issued an additional 29,305,819 fully paid ordinary shares to Nant Capital, LLC with a per share value of A$0.1859, for a total amount of A$5.45 million. In discussing the transaction, Chief Executive Officer, Greg West said, “In the second half of last year we said we would build the relationship with Nant through acquiring a clinical stage asset and by securing funding from Nant.” With this second tranche of share placement to Nant Capital, Nant now has a 28.57% interest in Benitec Biopharma. Benitec has reported a loss of A$3.02 million or A$1.19 a share on revenue of A$6.04 million for the six month ended in December 31, 2016. Revenue reported for the six months ended in December 31, 2015 were A$322,000, the significant increase in half yearly revenue year-on-year was mainly due to R&D grant amount of A$5.7 million, Benitec received from Australian Government during period from June to December 2016.

Access RDI’s Benitec Biopharma Research Report at: https://ub.rdinvesting.com/news/?ticker=BNTC

Regulus Therapeutics advanced 12.00% to close at $1.40 on Friday. The stock traded between $1.54 and $1.25 on volume of 4,282,684 shares traded. The U.S. based company focuses on the discovery and development of drugs that target microRNAs that are intended to treat a wide variety of diseases. Earlier this month, the research firm Wedbush continued to support its “outperform” rating on the company’s stock. Regulus has been assigned majority of ratings as “hold” by different investment research firms with consensus rating estimate of “overweight”.

Post its disclosure on January 27th, this year, a series of lawsuits have been filed by investors, as its new drug RG-101, against the chronic hepatitis C (HCV) virus infection will be placed on clinical hold due to another case of Jaundice. Regulus has reported fourth quarter results on March 2nd, where net loss for the fourth quarter and full year were $0.38 and $1.55 respectively. The company has reported cash, cash equivalents and short term investments of $76.1 million for the end of reporting year of 2016, compared to $115.3 million reported at the end of the previous reporting year. Paul Grint, M.D., President and Chief Executive Officer of Regulus stated, that he was even more convinced targeting microRNAs offers the potential for a significant advancement and therapeutic application for many diseases which currently exist limited or no treatment options.

Access RDI’s Regulus Therapeutics Research Report at: https://ub.rdinvesting.com/news/?ticker=RGLS

Our Actionable Research on Benitec Biopharma Ltd. (NASDAQ: BNTC) and Regulus Therapeutics Inc. (NASDAQ: RGLS) can be downloaded free of charge at Research Driven Investing.

Research Driven
Investing

RDInvesting has not been compensated; directly or indirectly; for producing or publishing this document.

CONTACT

For any questions, inquiries, or comments reach out to us directly at:

Address:

Research Driven Investing, Unit #901 511 Avenue of the Americas, New York, NY, 10011

Email:

contact@rdinvesting.com

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.

SOURCE: RDInvesting.com

ReleaseID: 458207

Banking Sector Rally Begins to Stall: Today’s Coverage on Bank of America and Citigroup

NEW YORK, NY / ACCESSWIRE / March 27, 2017 / Bank of America’s share price soared high today to close at $23.12 per share by the end of business today, representing a 0.22% increase in share price. With the ongoing cases against credit reporting agencies for giving falsified data on credit scores to customers, Financial Watchdog Consumer Financial Protection Bureau, on Thursday, imposed a $3 million fine on credit reporting agency Experian for deceiving customers on how their credit score would be used.

Credit Reporting agencies Equifax, TransUnion, and Experian have of late been subjected to hefty fines for deceiving customers about how their credit scores, accruing over $17 million in restitution to customers. The fines are on top of a $5.5 million payment to the CFPB. The credit reporting agencies, however, have denied any wrongdoing, saying they complied with the law. Bank of America has its credit score model, with the bank only using reporting agencies’ scores as “part of” their calculations.

Access RDI’s Bank of America Research Report at: https://ub.rdinvesting.com/news/?ticker=BAC

Citigroup’s shares closed the day on a high to trade at $58.07 a share, representing a 0.03% increase from the previous day’s share value. With the industry experiencing a strong run of results in the post-election era, the future looks bright. The industry, in general, has been expecting reduced regulations with the new president. The higher interest rates have also played a significant role in the sector’s recent up-rise.

Hedge fund manager Doug Kass has recently cited a slowing domestic economy, protectionism, and peak automotive sales and valuations in the banking sector as a threat to the financial health of the economy. He, however, attributes President Trump’s new fiscal and regulatory policies as favorable to the equities market. Credit reporting agencies are currently in the spotlight with their operations currently being monitored by the unforgiving CFPB. The upward trend in stock price, however, is a positive for the economy, as an upward trend in stock price bringing the much-needed optimism.

Access RDI’s Citigroup Research Report at: https://ub.rdinvesting.com/news/?ticker=C

Our Actionable Research on Bank of America Corp (NYSE: BAC) and Citigroup Inc. (NYSE: C) can be downloaded free of charge at Research Driven Investing.

RDI Initiates
Coverage on:

Bank of America Corp https://ub.rdinvesting.com/news/?ticker=BAC

Citigroup Inc. https://ub.rdinvesting.com/news/?ticker=C

Research Driven
Investing

RDInvesting has not been compensated; directly or indirectly; for producing or publishing this document.

CONTACT

For any questions, inquiries, or comments reach out to us directly at:

Address:

Research Driven Investing, Unit #901 511 Avenue of the Americas, New York, NY, 10011

Email:

contact@rdinvesting.com

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.

SOURCE: RDInvesting.com

ReleaseID: 458201

Twitter and GameStop Re-evaluate Their Market Models Based on Recent Competition

NEW YORK, NY / ACCESSWIRE / March 27, 2017 / Popular gaming store company GameStop and social media company Twitter are beginning to make shifts in their long term business strategies as the companies begin to evaluate current 4th quarter earnings reports. While neither company is in immediate distress, management is making changes to continue to remain competitive in the ever-changing worlds of social media and gaming.

RDI Initiates
Coverage:

Twitter Inc. https://ub.rdinvesting.com/news/?ticker=TWTR

GameStop Corp. https://ub.rdinvesting.com/news/?ticker=GME

Twitter’s shares advanced 1.41% to close at $15.14 a share on Friday. The stock traded within a $0.34 range between $15.37 and $15.03 on volume of 15.55 million shares traded. The news that is likely to change the investor perception of Twitter is that it is seeking to offer a subscription service that will offer those willing to pay up more information and tools. The service as a whole will remain free, but the decision to move in this direction is an admission that competing with Google and Facebook for ad revenues is a battle they are not likely to win.

Google and Facebook are about analytics. The direction Twitter is headed towards with their subscription service offer is a move towards being a news and information service – something the company has achieved a solid reputation for. With the current White House Administration, Twitter is likely to remain a primary media source of information. Twitter is still making losses and it currently has negative EPS of $0.65 a share.

Access RDI’s Twitter Research Report at: https://ub.rdinvesting.com/news/?ticker=TWTR

GameStop Corp stumbled 13.61% to close at $20.70 at the end of Friday’s trading session. The stock traded between $21.95 and $20.66 a share on volume of 15.94 million shares traded. The late week news has not been good for GameStop investors, as the company announced the closing of 150 stores. This came on the heels of an announcement by Chief Executive J. Paul Raines that sales and earnings fell by more than 10 percent as of the last reported fiscal quarter, and its discounted holiday shopping season had cost the company some market share.

One of GameStop’s strong plays is their collectibles stores which has grown almost 60% in 2016 with revenue of $494.1 million and Gamestop projects it to reach $1 billion by 2019. GameStop will open 35 new Collectible Stores in year 2017. GameStop at its inception depended on its business model of 100% videogame sales.

Access RDI’s GameStop Research Report at: https://ub.rdinvesting.com/news/?ticker=GME

Our Actionable Research on Twitter Inc. (NYSE: TWTR) and GameStop Corp. (NYSE: GME) can be downloaded free of charge at Research Driven Investing.

Research Driven
Investing

RDInvesting has not been compensated; directly or indirectly; for producing or publishing this document.

CONTACT

For any questions, inquiries, or comments reach out to us directly at:

Address:

Research Driven Investing, Unit #901 511 Avenue of the Americas, New York, NY, 10011

Email:

contact@rdinvesting.com

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.

SOURCE: RDInvesting.com

ReleaseID: 458209